Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
23.99
+0.01 (0.04%)
Dec 5, 2025, 4:00 PM EST - Market closed
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Pacira BioSciences stock have an average target of 33.83, with a low estimate of 18 and a high estimate of 65. The average target predicts an increase of 41.02% from the current stock price of 23.99.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pacira BioSciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +58.40% | Nov 17, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +16.72% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Maintains $32 → $30 | Strong Buy | Maintains | $32 → $30 | +25.05% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +33.39% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $65 | Strong Buy | Maintains | $48 → $65 | +170.95% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
744.73M
from 700.97M
Increased by 6.24%
Revenue Next Year
815.73M
from 744.73M
Increased by 9.53%
EPS This Year
3.02
from -2.15
EPS Next Year
3.44
from 3.02
Increased by 13.96%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 769.3M | 871.5M | ||||
| Avg | 744.7M | 815.7M | ||||
| Low | 710.2M | 759.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 9.8% | 17.0% | ||||
| Avg | 6.2% | 9.5% | ||||
| Low | 1.3% | 2.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.20 | 3.79 | ||||
| Avg | 3.02 | 3.44 | ||||
| Low | 2.81 | 3.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 25.6% | ||||
| Avg | - | 14.0% | ||||
| Low | - | 0.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.